Kiniksa Pharmaceuticals International (KNSA) Intangibles (2021 - 2026)

Kiniksa Pharmaceuticals International has reported Intangibles for 6 years, with the latest figure at $15.0 million in Q1 2026.

• For the quarter ending Q1 2026, Intangibles fell 6.25% year-over-year to $15.0 million; the trailing twelve-month figure through Mar 2026 stood at $15.0 million (down 6.25% YoY), and the FY2025 full-year result was $15.2 million, down 23.75% from the prior year.
• Intangibles for Q1 2026 stood at $15.0 million, down from $15.2 million in the prior quarter.
• The five-year high for Intangibles was $20.0 million in Q1 2022, with the low at $15.0 million in Q1 2026.
• Historically, Intangibles has averaged $17.8 million across 5 years, with a median of $17.2 million in 2023.
• Annual changes were most pronounced in 2024 — Intangibles rose 15.94% — and 2025, when it declined 23.75%.
• Kiniksa Pharmaceuticals International's Intangibles stood at $20.0 million in 2022, then decreased by 13.75% to $17.2 million in 2023, then advanced by 15.94% to $20.0 million in 2024, then declined by 23.75% to $15.2 million in 2025, then retreated by 1.64% to $15.0 million in 2026.
• The last three Intangibles figures came in at $15.0 million (Q1 2026), $15.2 million (Q4 2025), and $15.5 million (Q3 2025), per Business Quant data.